Skip to content

Trial · Interventional

CompletedPhase 4Registry data

Casodex/Zoladex Biomarkers in Localised Prostate Cancer

NCTNCT00293696 (opens ClinicalTrials.gov in a new tab)Other idD6876C00001
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Completed
Phase
Phase 4
Enrollment
30 participants (actual)
Sponsor
Tampere University · Other
Design
Randomized · Open label (no masking)
Countries
1 country

Finland

Start
Oct 2004
Primary completion
Not stated
Completion
Nov 2006
First posted
17 Feb 2006 (estimated)
Last update posted
8 May 2007 (estimated)
Conditions
Prostate Cancer

Timeline

1 trial · 1 completed

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
2004200520062007
  1. Ph 4

    Casodex/Zoladex Biomarkers in Localised Prostate Cancer

    NCT00293696

    Oct 2004 to Nov 2006

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

To evaluate anti-androgen (bicalutamide) induced biological and molecular changes in prostate comparison to chemical castration induced (goserelin) ones

Interventions

  • bicalutamide (Casodex), goserelin (Zoladex)Drug

Arms0

The registry lists no arms for this trial.

Primary outcomes3

Outcomes the sponsor listed as primary.

  1. Proliferation by Ki67,

  2. apoptosis marker (TUNEL assay),

  3. Gleason score

Secondary outcomes(3)

  1. expression of known androgen-regulated genes,

  2. biomarkers of apoptotic pathway,

  3. (novel) genomic transcripts

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

Completed trials do not always post results.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies0

Studies that cite this trial.

No study cites this trial.

Eligibility

Who could join, as posted.

Sex
Male
Age
from 18 Years up to 70 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: 1. Histologically confirmed localised prostate biopsy specimen that contains sufficient tumour for evaluation of cell proliferation and apoptosis markers 2. Patients who are scheduled for radical prostatectomy with curative intents

PepBank is a research reference. Talk to a doctor before you use any peptide.